List of investigational anxiolytics

This is a dynamic list and may never be able to satisfy particular standards for completeness. You can help by adding missing items with reliable sources.

This is a list of investigational anxiolytics , or anxiolytics that are currently under development for clinical use but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses.

This list was last comprehensively updated in June 2017. It is likely to become outdated with time.

Generalized anxiety disorder

• Riluzole sublingual (BHV-0223) – undefined mechanism of action ^[1]
• SPT-320 (LYT-320) – agomelatine prodrug (melatonin receptor agonist and serotonin 5-HT_2B and 5-HT_2C receptor antagonist) ^{[2] [3]}
• TGFK08AA – 5-HT_1A receptor modulator ^[4]
• TGW00AA (FKW00GA) – 5-HT_1A receptor agonist, 5-HT_2A receptor antagonist ^[5]

Panic disorder

• Darigabat (PF-06372865) – GABA_A receptor positive allosteric modulator ^[6]
• Tebideutorexant (JNJ-61393215, JNJ-3215) – orexin OX₁ receptor antagonist ^[7]

Post-traumatic stress disorder

• 7-Oxoprasterone (7-keto-DHEA; HBL-9001) – "immunomodulator" / undefined mechanism of action ^[8]
• Brexpiprazole (Lu AF41156, OPC-34712; Rexulti) – atypical antipsychotic / 5-HT_1A, D₂ and D₃ receptor partial agonist and 5-HT_2A, 5-HT_2B, 5-HT₇, α₁-adrenergic, α₂-adrenergic, and H₁ receptor antagonist ^[9]
• Iloperidone (HP-873, ILO-522; Fanapt, Fiapta, Zomaril) – atypical antipsychotic / 5-HT_2A, 5-HT₆, 5-HT₇, D₂, D₃, D₄, and α₁-adrenergic receptor antagonist ^[10]
• MDMA (Midomafetamine, 3,4-methylenedioxymethamphetamine, "ecstasy") – serotonin–norepinephrine–dopamine releasing agent and 5-HT₁ and 5-HT₂ receptor agonist – specifically under development as an aid to psychotherapy for post-traumatic stress disorder ^{[11] [12] [13]}
• NBTX-001 (Xenon) – NMDA receptor antagonist ^[14]
• Pomaglumetad methionil (DB-103, LY-2140023) – mGluR₂ and mGluR₃ agonist ^[15]
• Soclenicant (BNC-210; IW-2143) – "GABA Tooltip γ-aminobutyric acid modulator" ^[16] / undefined mechanism of action ^{[17] [18]}
• Tianeptine oxalate/naloxone (TNX-601) – atypical μ-opioid receptor agonist ^[19]

Social anxiety disorder

Main article: List of investigational social anxiety disorder drugs

• Fasedienol (Aloradine; PH94B; 4-androstadienol) – vomeropherine / neurosteroid ^[20]
• JNJ-42165279 – FAAH inhibitor ^{[21] [22]}
• TGW00AA (FKW00GA) – 5-HT_1A receptor agonist, 5-HT_2A receptor antagonist ^[5]

Others/unspecified

• Deuterated etifoxine (GRX-917) – translocator protein (TSPO) agonist and GABA_A receptor positive allosteric modulator ^{[23] [24]}
• JNJ-42165279 – FAAH inhibitor ^[25]
• JNJ-61393215 – orexin OX₁ receptor antagonist ^[7]
• Maritupirdine (AVN-101; Aviandr) – 5-HT₆ receptor antagonist ^[26]
• MP-20X – CB₁ and 5-HT_1A receptor modulator ^[27]
• Soclenicant (BNC-210; IW-2143) – "GABA modulator" ^[16] / undefined mechanism of action / α₇ subunit-containing nicotinic acetylcholine receptor antagonist ^{[17] [18]}
• SRX-246 – vasopressin V_1A receptor antagonist ^[28]
• Trideca-7,9,11-trienoic_acid - pharmacological mechanism of action unknown ^[29]

See also

• List of investigational drugs
• List of investigational social anxiety disorder drugs

References

1. "Riluzole sublingual - Biohaven Pharmaceuticals - AdisInsight". adisinsight.springer.com.
2. "SPT-320 - Seaport Therapeutics". AdisInsight. 2 January 2024. Retrieved 14 January 2025.
3. "Delving into the Latest Updates on SPT-320 with Synapse". Synapse. 21 November 2024. Retrieved 14 January 2025. By leveraging Glyph, SPT-320 bypasses liver first-pass metabolism, allowing for lower dosing and reduced liver exposure.
4. "TGFK 08AA - AdisInsight". adisinsight.springer.com.
5. "FKW 00GA - AdisInsight". adisinsight.springer.com.
6. "Darigabat - Cerevel Therapeutics - AdisInsight". adisinsight.springer.com.
7. "JNJ 61393215 - AdisInsight". adisinsight.springer.com.
8. "7-Oxoprasterone - Humanetics - AdisInsight". adisinsight.springer.com. Archived from the original on 2017-10-22.
9. "Brexpiprazole - Lundbeck/Otsuka - AdisInsight". adisinsight.springer.com.
10. "Iloperidone - Vanda Pharmaceuticals - AdisInsight". adisinsight.springer.com.
11. "Methylenedioxymetamfetamine - MAPS Europe B.V. - AdisInsight". adisinsight.springer.com.
12. Sessa B (2017). "MDMA and PTSD treatment: "PTSD: From novel pathophysiology to innovative therapeutics"". Neurosci. Lett. 649: 176–180. doi:10.1016/j.neulet.2016.07.004. PMID   27394687. S2CID   3803704.
13. Philipps D (29 November 2016). "F.D.A. Agrees to New Trials for Ecstasy as Relief for PTSD Patients". The New York Times. Retrieved 1 June 2017.
14. "NBTX 001 - AdisInsight". adisinsight.springer.com.
15. "Pomaglumetad methionil - Denovo Biopharma/Eli Lilly and Company - AdisInsight". adisinsight.springer.com.
16. Garakani A, Murrough JW, Iosifescu DV (2014). "Advances in Psychopharmacology for Anxiety Disorders". FOCUS. 12 (2): 152–162. doi: 10.1176/appi.focus.12.2.152 . ISSN   1541-4094.
17. Doggrell, S. A. (2007). Novel drugs and products in neuroscience. Drugs of the Future, 32(11), 1007-1017. https://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summary_pr?p_JournalId=2&p_RefId=3853&p_IsPs=Y
18. "BNC 210 - AdisInsight". adisinsight.springer.com.
19. "Naloxone/tianeptine - Tonix Pharmaceuticals - AdisInsight". adisinsight.springer.com.
20. "Fasedienol - Pherin Pharmaceuticals/VistaGen Therapeutics - AdisInsight". adisinsight.springer.com.
21. "JNJ 42165279 - AdisInsight". adisinsight.springer.com. Retrieved 2019-03-02.
22. "A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder | Clinical Research Trial Listing ( Claustrophobia ) ( NCT02432703 )". www.centerwatch.com. Retrieved 2019-03-02.
23. "Etifoxine deuterated - GABA Therapeutics - AdisInsight". adisinsight.springer.com.
24. Rupprecht R, Pradhan AK, Kufner M, Brunner LM, Nothdurfter C, Wein S, Schwarzbach J, Puig X, Rupprecht C, Rammes G (December 2022). "Neurosteroids and translocator protein 18 kDa (TSPO) in depression: implications for synaptic plasticity, cognition, and treatment options". Eur Arch Psychiatry Clin Neurosci. 273 (7): 1477–1487. doi:10.1007/s00406-022-01532-3. PMID   36574032. S2CID   255205221.
25. "JNJ 42165279 - AdisInsight". adisinsight.springer.com.
26. "AVN 101 - AdisInsight". adisinsight.springer.com.
27. "Medipure Pharmaceutical MP-20X product line for anxiety". medipurepharmaceuticals. Archived from the original on 2016-10-29.
28. "SRX 246 - AdisInsight". adisinsight.springer.com.
29. Shri R, Bhutani K, Sharma A (2010). "A new anxiolytic fatty acid from Aethusa cynapium". Fitoterapia. 81 (5): 337–340. doi:10.1016/j.fitote.2010.05.003. PMID   20472038. (https://www.academia.edu/4694323/A_new_anxiolytic_fatty_acid_from_Aethusa_cynapium)

External links

• AdisInsight – Springer
• 2016 Medicines in Development for Mental Health - PhRMA